4.7 Article

Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy

出版社

BMC
DOI: 10.1186/s13046-021-01993-9

关键词

Neuroblastoma; Cell surface protein; Nucleolin; Targeted therapy; Nanotechnology

类别

资金

  1. Italian ministry of Health under the frame of EuroNanoMed [ER-2015-2360441]
  2. Associazione Italiana per la Ricerca sul Cancro [18474, 24397]
  3. European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Program [CENTRO-01-0247-FEDER-017646]
  4. COMPETE 2020 - Operational Program for Competitiveness and Internationalisation and Portuguese national funds via FCT - Fundacao para a Ciencia e a Tecnologia, I.P. [POCI-01-0145-FEDER-016390, CENTRO-01-0145-FEDER-000012]
  5. CIBB (FCT) [UIDB/04539/2020]
  6. Italian Foundation for Neuroblastoma research and Associazione Oncologia Pediatrica E Neuroblastoma (OPEN) ONLUS

向作者/读者索取更多资源

This study showed that cell surface NCL is expressed in NB cell lines, NB tumor cells, and BM-infiltrating NB cells. The targeted nanoparticles decorated with the F3 peptide were effective in inhibiting cell proliferation and reducing tumor growth in NB animal models. NCL may be a promising therapeutic target for NB.
BackgroundNeuroblastoma (NB) represents the most frequent and aggressive form of extracranial solid tumor of infants. Nucleolin (NCL) is a protein overexpressed and partially localized on the cell surface of tumor cells of adult cancers. Little is known about NCL and pediatric tumors and nothing is reported about cell surface NCL and NB.MethodsNB cell lines, Schwannian stroma-poor NB tumors and bone marrow (BM)-infiltrating NB cells were evaluated for the expression of cell surface NCL by Flow Cytometry, Imaging Flow Cytometry and Immunohistochemistry analyses. The cytotoxic activity of doxorubicin (DXR)-loaded nanocarriers decorated with the NCL-recognizing F3 peptide (T-DXR) was evaluated in terms of inhibition of NB cell proliferation and induction of cell death in vitro, whereas metastatic and orthotopic animal models of NB were used to examine their in vivo anti-tumor potential.ResultsNB cell lines, NB tumor cells (including patient-derived and Patient-Derived Xenografts-PDX) and 70% of BM-infiltrating NB cells show cell surface NCL expression. NCL staining was evident on both tumor and endothelial tumor cells in NB xenografts. F3 peptide-targeted nanoparticles, co-localizing with cell surface NCL, strongly associates with NB cells showing selective tumor cell internalization. T-DXR result significantly more effective, in terms of inhibition of cell proliferation and reduction of cell viability in vitro, and in terms of delay of tumor growth in all NB animal model tested, when compared to both control mice and those treated with the untargeted formulation.ConclusionsOur findings demonstrate that NCL could represent an innovative therapeutic cellular target for NB.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据